Adaptive Biotechnologies Corporation (FRA:1HM)

Market Cap	1.94B
Revenue (ttm)	215.42M
Net Income (ttm)	-67.85M
Shares Out	n/a
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87
Average Volume	116
Open	14.76
Previous Close	14.57
Day's Range	13.40 - 14.76
52-Week Range	5.60 - 17.71
Beta	n/a
RSI	52.63
Earnings Date	Feb 13, 2026

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as M...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2009
• Employees: 619
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1HM

Financial Performance

In 2024, Adaptive Biotechnologies's revenue was $178.96 million, an increase of 5.10% compared to the previous year's $170.28 million. Losses were -$159.49 million, -29.19% less than in 2023.

Financial numbers in USD